Merck’s Keytruda sales eclipse $18B on the year, while numbers for Lagevrio surprise

Mer­ck’s block­buster can­cer drug Keytru­da made $18.4 bil­lion in the first nine months of the year — near­ly the same amount as the re­port­ed rev­enue of the NFL in 2022.

In the third quar­ter of 2023, Mer­ck re­port­ed $6.3 bil­lion in Keytru­da sales, slight­ly high­er than Wall Street ex­pec­ta­tions. Mer­ck ex­pects about 20% of its Keytru­da sales this year to come from ear­li­er-stage can­cer in­di­ca­tions, chief fi­nan­cial of­fi­cer Car­o­line Litch­field said in an an­a­lyst call Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.